Global AI Infrastructure Shift Ignites Biotech Growth Phase
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: GlobeNewswire
Issued on behalf of Aleen Inc. VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Last month marked a major turning point as Google launched Gemini 3[1], proving that new AI models can now outperform humans on critical tasks. At the same time, global regulators accelerated the shift[2] toward strict rules for AI in medical devices, signaling that the technology is finally ready for real-world commercial use. This rapid move from the lab to the mass market creates a massive opportunity for specialized operators including Aleen Inc. (CSE: ALEN-U), Moderna, Inc. (NASDAQ: MRNA), GE HealthCare (NASDAQ: GEHC), CeriBell, Inc. (NASDAQ: CBLL), and Palantir Technologies Inc. (NASDAQ: PLTR). New data from December 2025 predicts the AI in healthcare market[3] will hit $505.59 billion by 2033 as adoption speeds up. This boom is fueled by a huge workforce change, with leaders like [Accenture rebranding 800,000 employees[4] to focus entirely on using
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna (NASDAQ:MRNA) was given a new $28.00 price target on by analysts at Morgan Stanley.MarketBeat
- Moderna (NASDAQ:MRNA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "hold" rating on the stock.MarketBeat
- Moderna (NASDAQ:MRNA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Moderna (NASDAQ:MRNA) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Moderna (NASDAQ:MRNA) was given a new $18.00 price target on by analysts at UBS Group AG.MarketBeat
MRNA
Earnings
- 11/6/25 - Beat
MRNA
Sec Filings
- 12/11/25 - Form 144
- 12/11/25 - Form 4
- 12/9/25 - Form 144
- MRNA's page on the SEC website